Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD45RA-depleted haploidentical hematopoietic progenitor cell and natural killer cell therapy
- Development stage
- Unknown
- Lead developer
- St. Jude Children's Research Hospital
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Stem Cell Therapies → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
This investigational cellular therapy, developed by St. Jude Children's Research Hospital, is a specialized form of haploidentical (half-matched) hematopoietic progenitor cell transplantation (HPCT) designed for pediatric patients with high-risk or relapsed/refractory hematologic malignancies. The approach involves the selective depletion of CD45RA+ naive T cells from the donor graft to minimize the risk of graft-versus-host disease (GvHD) while preserving CD45RO+ memory T cells to facilitate rapid immune reconstitution and protection against viral infections. This is combined with the infusion of donor-derived natural killer (NK) cells to enhance the graft-versus-leukemia (GvL) effect. The therapy is typically administered following a reduced-intensity conditioning regimen and is being evaluated for conditions such as acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and myelodysplastic syndrome (MDS).
- Other names
- CD45RA-depleted haploidentical HPC and NK cell transplantCD-45RA-depleted haploidentical HPC and NK cell transplantCD 45RA-depleted haploidentical HPC and NK cell transplantCD45RA-depleted haploidentical transplantationCD-45RA-depleted haploidentical transplantationCD 45RA-depleted haploidentical transplantationCD45RA-depleted haploidentical hematopoietic progenitor cell and natural killer cell transplantationCD-45RA-depleted haploidentical hematopoietic progenitor cell and natural killer cell transplantationCD 45RA-depleted haploidentical hematopoietic progenitor cell and natural killer cell transplantation
Beyond the preview
Go deeper on CD45RA-depleted haploidentical hematopoietic progenitor cell and natural killer cell therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD45RA-depleted haploidentical hematopoietic progenitor cell and natural killer cell therapy.